Peg-Ancount Injection

About

Peg-Ancount Injection is a pegylated form of granulocyte colony-stimulating factor (G-CSF), a naturally occurring protein that stimulates the production, maturation, and activation of neutrophils, a type of white blood cell crucial for fighting infection. By administering a pegylated form, the drug's half-life is significantly extended, allowing for a single dose per chemotherapy cycle rather than daily injections. It is primarily used to reduce the incidence of febrile neutropenia, a serious complication of myelosuppressive chemotherapy that can lead to life-threatening infections. By boosting neutrophil counts, it helps maintain the patient's immune defense, allowing them to complete their chemotherapy regimen on schedule and with reduced risk of infection-related morbidity and mortality.

Uses

• Reduction of incidence of febrile neutropenia in cancer patients.
• Prevention of infection associated with myelosuppressive chemotherapy.
• Supportive care during chemotherapy regimens.
• Used in patients receiving chemotherapy with a high risk of neutropenia.

Directions For Use

Administered as a single subcutaneous injection once per chemotherapy cycle, typically 24 hours after chemotherapy.

Benefits

• Significantly reduces the risk of febrile neutropenia.
• Decreases the incidence of infection during chemotherapy.
• Allows patients to maintain chemotherapy schedules.
• Reduces hospitalizations due to neutropenic complications.
• Convenient single-dose administration per cycle.
• Improves patient safety and treatment adherence.

Side Effects

• Bone pain (common)
• Myalgia (muscle pain)
• Headache
• Fatigue
• Nausea
• Injection site reactions
• Splenomegaly (rare)
• Splenic rupture (very rare)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Leukocytosis
• Allergic reactions

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but general moderation is advised during cancer treatment.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus. Consult your doctor.
• Breastfeeding - It is unknown if this drug is excreted in human milk. Exercise caution; consult a healthcare professional.
• Liver - No specific dose adjustment is typically required for patients with liver impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment.
• Lung - Monitor for pulmonary adverse reactions such as interstitial lung disease or ARDS, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.